INTRODUCTION
Hematopoietic stem cells (HSCs) persist throughout life by undergoing self-renewing divisions regulated by networks of proto-oncogenes and tumor suppressors (He et al., 2009 ). Mechanisms that promote HSC self-renewal are commonly overactivated or ectopically activated in leukemia cells (Reya et al., 2001 ). These self-renewal mechanisms are co-opted by leukemia cells irrespective of whether they arise from HSCs or from restricted progenitors (Krivtsov et al., 2006) . HSC properties and self-renewal mechanisms change over time. The transcription factor Sox17 is required for the maintenance of fetal and neonatal, but not adult, HSCs (Kim et al., 2007) . Conversely, the epigenetic/transcriptional regulators Bmi-1, Tel/Etv6, and Gfi-1 regulate the maintenance of postnatal, but not fetal, HSCs (Lessard and Sauvageau, 2003; Park et al., 2003; Hock et al., 2004a Hock et al., , 2004b . The temporal changes in HSC self-renewal mechanisms raise the question of whether the driver mutations that are competent to cause leukemia also change over time.
Hematopoietic malignancies occur throughout life and the incidence of specific driver mutations varies with patient age, even within the same subtype of leukemia (Downing and Shannon, 2002) . Myeloid leukemias in young children are often driven by translocations involving transcription factors (Downing and Shannon, 2002) . In contrast, myeloid leukemias in older children and adults are much more likely to have mutations that activate the PI3-kinase pathway, including Bcr-Abl and Flt3 internal tandem duplications (Meshinchi et al., 2001; Zwaan et al., 2003; Martelli et al., 2006; Kharas et al., 2008 Kharas et al., , 2010 . These observations raise the question of whether age-dependent changes in leukemia driver mutations occur because of developmental changes in signaling mechanisms that regulate self-renewal.
The Pten tumor suppressor negatively regulates PI3-kinase pathway signaling and is commonly inactivated in many cancers (Di Cristofano and Pandolfi, 2000) . Pten loss-of-function mutations occur frequently in T-precursor ALL (T-ALL) and Pten is inactivated in some acute myeloid leukemias (AMLs) by mutations, promoter methylation, or transcriptional repression (Dahia et al., 1999; Gutierrez et al., 2009; Larson Gedman et al., 2009; Yoshimi et al., 2011) . While B-ALL usually presents in young children and rarely involves Pten deletion (Mullighan et al., 2011) , pediatric T-ALL exhibits an older mean age of presentation ($9-10 years of age) (Smith et al., 1999; Clappier et al., 2007; Karrman et al., 2009 ) and commonly involves Pten deletion or other mutations that activate PI3-kinase pathway signaling (Gutierrez et al., 2009) .
One possibility is that PI3-kinase pathway regulation changes over time in hematopoietic cells. Pten deletion from hematopoietic cells in adult mice leads to the development of T-ALL Zhang et al., 2006; Guo et al., 2008; Lee et al., 2010) . Pten deletion from adult mouse HSCs causes these cells to go into cycle and to be depleted by a tumor suppressor response induced by hyperactivation of mTOR Lee et al., 2010) . Both leukemogenesis and HSC depletion after Pten deletion can be rescued by treating mice with rapamycin . This suggests that these phenotypes are mediated by RAPTOR/mTORC1 activation; however, rapamycin can also indirectly inhibit RICTOR/mTORC2 signaling (Sarbassov et al., 2006) , and mTORC1 activation is influenced by mTORC2 signaling (Guertin and Sabatini, 2007; Guertin et al., 2009) . Consequently, the relative contribution of mTORC1 and mTORC2 to these phenotypes is uncertain. It also remains unclear whether Pten deletion drives HSCs into cycle by activating physiological mechanisms that induce HSC division or by activating mechanisms that do not normally regulate HSC division.
To address these questions we evaluated PTEN function, RICTOR/mTORC2 function, and PI3-kinase pathway activation in fetal, neonatal, and adult HSCs. AKT phosphorylation did not detectably increase in HSCs that divided under physiological conditions. Consistent with this, Rictor deletion had little effect on HSC frequency or function. However, Rictor deletion largely rescued the increased AKT phosphorylation, HSC depletion, and leukemogenesis observed after Pten deletion from adult HSCs. This suggests that Pten deletion promotes HSC proliferation by activating signaling pathways that have a limited role (n = 3), and cyclophosphamide/G-CSF-treated adult mice (n = 3). All comparisons are relative to 8-week-old adult mice (*p < 0.05; **p < 0.01; ***p < 0.001 in HSC self-renewal under physiological conditions. The observation that Pten deletion provides no selective advantage to neonatal hematopoietic cells may explain why Pten mutations are rare in leukemias that affect young children. Temporal changes in the signaling mechanisms that regulate self-renewal lead to temporal changes in leukemogenic mechanisms.
RESULTS
Normal HSC Proliferation Is Not Associated with Increased AKT Phosphorylation HSCs divide rapidly during fetal and neonatal development (Morrison et al., 1995) and after cyclophosphamide/G-CSF treatment (Morrison et al., 1997) . We compared the cell cycle status of
isolated from embryonic day (E)14.5 fetal mice, postnatal day (P)14 neonatal mice, 8-week-old adult mice, and mice that were treated with cyclophosphamide and two daily doses of G-CSF (Figures 1A and 1B;  Table S1 available online). We also administered poly-inosine:poly-cytosine (pIpC) to Mx1-Cre; Pten fl/fl mice 6 weeks after birth and isolated HSCs for cell cycle analysis at 8 weeks after birth. The fraction of HSCs in S/G2/M phases of the cell cycle decreased significantly from E14.5 to P14 to 8 weeks after birth ( Figure 1B ). The frequency of HSCs in S/G2/M phases of the cell cycle after cyclophosphamide/G-CSF treatment was significantly greater than after Pten deletion ( Figure 1B ). To assess whether AKT activation correlates with the frequency of HSCs/MPPs in cycle, we compared AKT phosphorylation between CD48
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HSCs/MPPs (Kiel et al., 2005; Kim et al., 2006 ) from E14.5 fetal liver, P14 bone marrow, 8-week-old adult wild-type bone marrow, and 8-week-old bone marrow after Pten deletion from Mx1-Cre; Pten fl/fl mice. The cell cycle distribution in the HSC/ MPP population was similar to that of highly purified HSCs (Figure 1C) , consistent with prior studies (Foudi et al., 2009) . As expected, AKT and S6 were more highly phosphorylated in Ptendeficient adult HSCs/MPPs as compared to wild-type adult HSCs/MPPs ( Figure 1D ). However, phosphorylated AKT levels were lower in fetal and neonatal HSCs/MPPs compared to normal adult HSCs/MPPs ( Figure 1D ), even though fetal and neonatal HSCs/MPPs were more mitotically active ( Figure 1C) . Levels of phosphorylated S6 were higher in fetal HSCs/MPPs but lower in neonatal HSCs/MPPs as compared to adult HSCs/ MPPs ( Figure 1D ). Phosphorylated AMPK and GSK3b levels did not significantly differ between fetal, neonatal, and adult HSCs/MPPs. Fetal HSCs/MPPs in G0/G1 versus S/G2/M phases of the cell cycle exhibited similar levels of AKT phosphorylation ( Figure 1E ).
We next evaluated AKT and S6 phosphorylation in sorted HSCs/MPPs from the bone marrow of untreated or cyclophosphamide/G-CSF-treated 8-week-old adult mice. After cyclophosphamide and 2 days of G-CSF, HSCs/MPPs did not exhibit increased AKT or S6 phosphorylation ( Figure 1F ) despite the high percentage of cells in S/G2/M ( Figures 1B and 1C Figure 1F ). CD48 À LSK cells were also harvested from the spleens of mice treated with cyclophosphamide and 4 days of G-CSF. HSCs/MPPs from these mice still did not exhibit increased AKT phosphorylation relative to normal adult HSCs, though an increase in 4EBP phosphorylation was observed ( Figure 1G ). Rapidly dividing HSCs therefore exhibit little or no increase in AKT phosphorylation relative to quiescent adult HSCs.
Pten Is Required by Adult, but Not Neonatal, HSCs To determine whether Pten regulates neonatal HSCs, we induced Cre in Mx1-Cre; Pten fl/fl mice by administering a single subcutaneous dose of pIpC 2 days after birth, resulting in complete Pten deletion in HSCs ( Figure S1 available online). Bromo-deoxyuridine (BrdU) was then administered for 24 hr before the mice were sacrificed (Figures 2A and 2B ). The overall proliferation of unfractionated bone marrow cells at 2, 3, 4, and 5 weeks after birth was not affected by Pten deletion (Figure 2A to 5 (10% ± 6.8%) weeks after birth as HSCs made the transition to a more slowly dividing adult phenotype ( Figure 2B ). Pten deletion had no effect on BrdU incorporation into HSCs at 2 weeks after birth, but Pten-deficient HSCs showed a trend toward increased BrdU incorporation relative to control HSCs at 3 weeks after birth, and the effect was statistically significant at 4 and 5 weeks after birth ( Figure 2B ). To determine whether Pten deletion mobilizes neonatal HSCs, we administered pIpC to 2-day-old neonatal mice or to 6-weekold adult mice, then measured the number of HSCs per spleen at 2, 4, and 8 weeks after birth ( Figure 2C ). We observed a >40-fold increase in the number of HSCs in the spleens of 8-week-old adult mice (2 weeks after Pten deletion; Figure 2C ). In contrast, Pten deletion had no effect on the number of HSCs in the spleen of 2-week-old mice and only modestly (but significantly) increased the number of HSCs in the spleens of 4-week-old mice ( Figure 2C ). We also did not observe any effect of Pten deletion on the overall proliferation of splenocytes until 4 weeks after birth ( Figure 2D ). Pten deletion therefore does not lead to increased HSC proliferation or mobilization until around 4 weeks after birth.
We compared the reconstituting capacity of HSCs from neonatal and adult mice after Pten deletion at 2 days or 6 weeks after birth. We transplanted 10 CD45. Figures 2M and 2N ).
Pten is therefore not required to prevent myeloproliferative disorder in neonatal mice. When Pten is deleted from young adult mice they succumb to T-ALL by 12 weeks after Cre induction Lee et al., 2010) . This latency period makes it difficult to test whether Pten deletion is leukemogenic in neonatal mice because they would mature into adults before the onset of leukemia; therefore, to test whether Pten is a tumor suppressor in neonatal mice, we deleted Pten from p53-deficient mice. In adult mice this greatly accelerates leukemogenesis (Lee et al., 2010 ; p53 À/À mice that had been treated with pIpC at 2 days of age showed any signs of illness ( Figure 3A ). These mice did not die until 44 to 60 days after pIpC treatment, when they were 6-to 8-week-old adults ( Figure 3A) . (C) The numbers of HSCs in the spleens of mice that received pIpC 2 days after birth then were then analyzed at 2 or 4 weeks after birth, or those that received pIpC at 6 weeks after birth were then analyzed 8 weeks after birth (n = 4-10 mice per genotype, *p < 0.05; ***p < 0.0001). (D) Splenocyte BrdU incorporation (24 hr BrdU pulse; n = 3-4 mice per time point and genotype; **p < 0.01). (E-H) Long-term competitive repopulation assays with 10 wild-type or Pten-deficient (Pten D/D) adult or neonatal HSCs (n = 7-10 recipients/age/genotype; *p < 0.05; **p < 0.01; ***p < 0.001). The threshold at which donor cells could be detected above background (in negative control mice, 0.5%) is indicated by the black line. (I and J) Spleen cellularity (I) and mass (J) for Pten-deleted adult and neonatal Mx1-Cre; Pten fl/fl mice as well as littermate controls 2 weeks after pIpC treatment (n = 10-13 mice/age/genotype; *p < 0.05; ***p < 1 3 10 À10 ).
(K-N) Representative low power (403) of T-ALL), none of the neonatally treated mice showed any signs of illness or leukemia: they had normal thymus and spleen histology ( Figures 3I-3L) ; however, when these mice became ill approximately 50 days after pIpC treatment, they had large mediastinal masses and infiltrative T-ALL ( Figures 3M-3P ). The observation that Mx1-Cre; Pten fl/fl ; p53 À/À mice succumbed to leukemia at the same time, irrespective of whether Pten was deleted 2 days or 6 weeks after birth ( Figure 3C ), demonstrates that an adult developmental context is required for leukemia after Pten deletion. We performed similar experiments in mice with a p53 heterozygous background and obtained similar results ( Figures 3B and 3D ). 4B ). Pten deletion did not increase AKT phosphorylation in HSCs/MPPs until 3 to 4 weeks after birth ( Figure 4C ), the same time we began to observe increased HSC proliferation after Pten deletion ( Figure 2B ).
To determine whether neonatal HSCs/MPPs are capable of activating the PI3-kinase pathway, we incubated neonatal or adult HSCs/MPPs from control and Mx1-Cre; Pten fl/fl mice in culture with 2% fetal bovine serum at 37 C for 30 min. In contrast to uncultured neonatal Pten-deficient HSCs/MPPs, phosphorylated AKT was present at comparable levels in neonatal versus adult Pten-deficient HSCs/MPPs ( Figure 4D ). Neonatal HSCs are therefore capable of phosphorylating AKT when exposed to serum in culture and PTEN negatively regulates this process. Several PI3K pathway proteins, including AKT, S6, RICTOR, mTOR, RAPTOR, and SHIP1, are expressed at similar levels in neonatal and adult HSCs (Figures 4A, 4B , and 4E). Phosphorylation of mTOR at Ser2481, which reflects mTORC2 function (Copp et al., 2009 ), was also similar in neonatal and adult HSCs/MPPs ( Figure 4F ). A number of other gene products known to regulate the PI3-kinase pathway were expressed at similar levels in neonatal and adult HSCs by quantitative RT-PCR ( Figure S2A ). Neonatal HSCs/MPPs are therefore capable of activating the PI3-kinase pathway, but PTEN is not required in neonatal HSCs/MPPs in vivo to negatively regulate pathway activation.
Neonatal restricted progenitors (CD48 + LSK cells) and unfractionated bone marrow cells did exhibit increased AKT phosphorylation following Pten deletion ( Figure 4G ). Pten deletion also increased AKT and S6 phosphorylation in lymphoid primed multipotent progenitors (Lineage À c-kit
LMPPs) and GMPs from neonatal and adult mice ( Figure 4H ). In contrast, adult CD4 + CD8 + thymocytes had much higher levels of AKT and S6 phosphorylation after Pten deletion than neonatal CD4 + CD8 + thymocytes ( Figure 4I ). As in prior studies Zhang et al., 2006) , we observed an increase in myelopoiesis and a decrease in B lymphopoiesis in adult bone marrow after Pten deletion. We also observed an increase in myelopoiesis and a decrease in B lymphopoiesis in the bone marrow and spleen of neonatal mice after Pten deletion ( Figures  4J and 4K ). These data demonstrate that many restricted hematopoietic progenitors in neonatal mice depend upon PTEN to regulate cellular signaling and function, just as observed in adult mice, but that HSCs and T lineage progenitors undergo a temporal change in their dependence upon PTEN between the neonatal and adult stages.
To further explore the differences in PI3-kinase pathway regulation between neonatal and adult HSCs, we compared the gene expression profiles of P14 neonatal HSCs and 8-week-old adult HSCs from wild-type mice. We identified 14 genes that were significantly more highly expressed in neonatal HSCs, and 21 genes that were significantly more highly expressed in adult HSCs (Table S2 ; fold change >2.0). Ten of these genes could potentially regulate PI3-kinase pathway signaling based on prior studies. The differential expression of eight of these genes was confirmed by quantitative RT-PCR ( Figure S2B , Table S3 ). For example, Bank1 was expressed more highly in neonatal relative to adult HSCs ( Figure S2B ) and is known to negatively regulate AKT phosphorylation (Aiba et al., 2006) . This provides candidate genes that could potentially explain the difference in PTEN dependence between neonatal and adult HSCs, but gene-targeted mice will have to be generated to functionally test these hypotheses.
Rictor Deletion Reduces AKT Phosphorylation in Primitive Hematopoietic Progenitors We next assessed the mechanisms by which Pten deletion promotes HSC depletion and leukemogenesis in adult mice. Pten deletion can activate both mTORC1 and mTORC2 (Guertin and Sabatini, 2007) ; however, mTORC1 promotes proliferation by phosphorylating S6 kinase and 4EBP1 while mTORC2 phosphorylates AKT at Ser473 (Guertin et al., 2006; Guertin and Sabatini, 2007) . Since increased AKT phosphorylation at Ser473 distinguished Pten-deficient HSCs from HSCs that were dividing under physiological conditions ( Figure 1C ), we tested whether the effects of Pten deficiency were mediated by increased mTORC2 activation. We generated a floxed allele that allowed us to conditionally delete Rictor (Figure S3 ), a key component of the mTORC2 complex (Guertin et al., 2006) , and we generated Mx1-Cre; Rictor fl/fl mice. We administered pIpC 6 weeks after birth and observed an almost complete loss of RICTOR protein from Mx1-Cre; Rictor fl/fl LSK cells, but mTOR was still expressed ( Figure 4L ). We confirmed that both Rictor alleles were recombined in all HSCs tested ( Figure S4A ).
To Pten fl/fl LSK cells, and Torin1 treatment completely blocked AKT phosphorylation at Thr308 even though this site is not thought to be an mTORC1 or mTORC2 substrate ( Figure 4N) . A similar decrease in Thr308 phosphorylation was previously observed in Rictor-deficient prostate epithelium (Guertin et al., 2009 Figure 5A ; Figure S4E ). We also deleted Rictor 2 days after birth by administering a single dose of pIpC to Mx1-Cre; Rictor fl/fl mice to achieve complete recombination of the Rictor fl alleles (Figure S4B) . At P14 we did not observe significant differences in the frequency or absolute number of bone marrow HSCs between Mx1-Cre; Rictor fl/fl mice and littermate controls
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Temporal Changes in Signaling in Stem Cells ( Figure 5A ; Figure S4E ). Rictor is therefore not necessary for the formation of HSCs or for fetal/neonatal hematopoiesis. mice that received pIpC at P2. We did not observe significant differences between control and Rictor-deficient HSCs in the frequency of HSCs in S/G2/M phases of the cell cycle in either genetic background ( Figure 5B ). We also observed no significant difference in the BrdU incorporation rate of Rictor-deficient and control HSCs ( Figure 5C ). Rictor is therefore not required to regulate the maintenance or cell cycle of neonatal HSCs.
To determine whether Rictor regulates adult hematopoiesis or HSC function, we administered pIpC to adult Mx1-Cre; Rictor fl/fl mice and littermate controls 6 weeks after birth. These mice were observed for 18-24 weeks following pIpC treatment and they did not develop any overt signs of illness (data not shown). After the observation period, we detected a small, but significant, decrease in white blood cell counts in Rictor-deleted mice ( Figure S4F ), but red blood cell counts (Figure S4G) , platelet counts ( Figure S4H ), and thymus cellularity ( Figure S4I ) were not significantly affected by Rictor deletion. We observed a trend toward reduced spleen cellularity in multiple experiments but the effects were not statistically significant ( Figure S4L ). We also observed no significant difference in bone marrow cellularity, HSC frequency, or absolute HSC numbers ( Figures 5D-5F ). We did observe a significant reduction in the frequency of MPPs (CD150 (Figures 5E and 5F ). Rictor is therefore not required for the maintenance of adult HSCs, but RICTOR may regulate MPPs.
Rictor-deficient bone marrow cells gave long-term multilineage reconstitution of all recipient mice for at least 16 weeks after transplantation (Figures 5G-5K) . We observed significantly reduced levels of donor lymphocyte reconstitution in recipients of Rictor-deficient bone marrow cells over the first 12 weeks after transplantation, but this difference was not significant by 16 weeks after transplantation ( Figures 5I and 5J) . We did not observe any differences in the frequency of donor HSCs or MPPs in recipients of Rictor-deficient or control cells 16 weeks after transplantation ( Figure 5L ). We also did not observe significant differences in the reconstituting capacity of Rictor-deficient and control bone marrow cells in secondary recipients ( Figures 5M and 5N) . Rictor is therefore not necessary for HSC maintenance or function in normal adult mice, though its absence may lead to modest deficits in lymphoid reconstitution. (G-K) Ten CD45.2+ donor HSCs from Pten-deficient mice failed to give long-term multilineage reconstitution in irradiated mice. Rictor-deficient HSCs gave long-term multilineage reconstitution in 3 of 12 recipient mice, but levels of donor cell reconstitution were generally lower than observed from control HSCs. Pten; Rictor compound-deficient HSCs were able to give long-term multilineage reconstitution in nearly all irradiated mice at levels similar to those of control HSCs, with the exception of the B cell lineage (I) (n = 12-16 mice/ genotype).
(L-P) Following secondary transplantation, Rictordeficient and Pten; Rictor compound-deficient donor cells gave long-term multilineage reconstitution of nearly all secondary recipient mice (n = 9-22 mice/genotype). Error bars represent standard deviation and p values were calculated by two-tailed Student's t tests: *p < 0.05; **p < 0.01; ***p < 0.001; N.S., not significant (p > 0.05).
Rictor Is Necessary for Adult HSC Proliferation and Depletion after Pten Deletion We administered pIpC to control, Mx1-Cre; Pten fl/fl , Mx1-Cre; Rictor fl/fl , and Mx1-Cre; Pten fl/fl ; Rictor fl/fl mice 6 weeks after birth and analyzed HSCs 2 weeks later. Since rapamycin rescues the proliferation of Pten-deficient HSCs , we also administered rapamycin to some Mx1-Cre; Pten fl/fl mice and controls for 1 week prior to analysis. Rapamycin did not appear to affect mTORC2 function in primitive hematopoietic progenitors as it did not affect AKT phosphorylation at Ser473 in Pten-deficient LSK cells in vivo (7 days at 4 mg/kg/day; Figure 6A ), or after 30 min of culture in rapamycin-containing medium (100 nm; Figure 6B ). In contrast, Rictor deletion may modestly reduce mTORC1 activation as phosphorylated S6 levels were modestly reduced in Rictor-deficient as compared to control LSK cells and phosphorylated S6 levels were reduced as a fraction of total S6 levels in Figure 4N ). A decline in mTORC1 signaling after Rictor deletion may be expected as mTORC2 signaling increases AKT signaling and therefore mTORC1 activation (Guertin and Sabatini, 2007; Guertin et al., 2009) . In primitive hematopoietic progenitors rapamycin thus appears to reduce mTORC1 function without affecting mTORC2 while Rictor deletion appears to eliminate mTORC2 function while modestly reducing mTORC1 function.
Pten deletion significantly increased the fraction of HSCs in S/G2/M phases of the cell cycle and rapamycin rescued this effect ( Figure 6C) . Rictor deletion by itself did not significantly affect the frequency of HSCs in S/G2/M phases of the cell cycle but did significantly reduce the fraction of Pten-deficient HSCs in S/G2/M phases of the cell cycle ( Figure 6C ). Treating Pten/Rictor compound mutant mice with rapamycin did not further reduce HSC proliferation. Rictor deletion also significantly reduced the mobilization of Pten-deficient HSCs but rapamycin had no effect ( Figure 6D ). Taken together this suggests that mTORC2 mediates the effects of Pten deletion on HSC function through mTORC1-dependent and mTORC1-independent mechanisms, consistent with studies in other cell types (Guertin and Sabatini, 2007) .
Rapamycin treatment, but not Rictor deletion, reduced the mobilization of wild-type HSCs from the bone marrow to the spleen after cyclophosphamide/G-CSF treatment ( Figures 6E  and 6F ). This suggests that mTORC1, not mTORC2, is the major mediator of HSC proliferation under physiological conditions in wild-type mice. This conclusion is consistent with the paucity of Ser473 phosphorylation of AKT (an mTORC2 site; Guertin et al., 2006) in fetal, neonatal, and cyclophosphamide/G-CSF mobilized HSCs (Figures 1D-1G ) and with the lack of effect of Rictor deletion on HSC frequency or proliferation ( Figure 5 ). Pten deletion therefore induces the proliferation and mobilization of HSCs through mTORC2-dependent mechanisms that do not mimic physiological HSC self-renewal mechanisms.
To test if Rictor is necessary for the depletion of Pten-deficient HSCs, we administered pIpC to 6-week-old control, Figures 6G-6K ). Rictor-deficient HSCs gave long-term multilineage reconstitution in 3 of 12 recipient mice. Most of the remaining mice had long-term myeloid reconstitution, suggesting that HSC activity was maintained in these mice, but they did not necessarily have long-term lymphoid reconstitution ( Figures  6G-6K) . In contrast to Pten-deficient HSCs, Pten; Rictor compound mutant HSCs gave long-term multilineage reconstitution in almost all recipient mice with levels of donor myeloid and T cell reconstitution that were at least as high as from control HSCs (Figures 6G-6K ). Pten; Rictor compound mutant HSCs gave much lower levels of B lineage reconstitution than control HSCs ( Figure 6I ), suggesting that Rictor deficiency largely rescued the function of Pten-deficient HSCs but did not rescue the function of Pten-deficient B lineage progenitors. Figure 7A ). Rapamycin in Mx1-Cre; Pten fl/fl ; Rictor fl/fl mice further reduced spleen cellularity, rendering it similar to control spleens (Figure 7A) . Rictor deletion and rapamycin treatment therefore additively reduce the severity of myeloproliferative disorder after Pten deletion, suggesting that mTORC1 and mTORC2 both contribute to this phenotype ( Figure 7A ). Nonetheless, extramedullary hematopoiesis was still histologically evident in the spleens of rapamycin-treated Mx1-Cre; Pten fl/fl ; Rictor fl/fl mice, suggesting that rapamycin treatment and Rictor deletion did not completely eliminate the myeloproliferative disorder ( Figure S5 ). To determine whether Rictor is necessary for progression to acute leukemia following Pten deletion, we administered pIpC to control, PI3-kinase pathway by Pten deletion, overexpression of Akt1, or Tsc2 deletion promotes adult HSC proliferation and HSC depletion Zhang et al., 2006; Chen et al., 2008; Gan et al., 2008; Kharas et al., 2010; Lee et al., 2010) . However, fetal and neonatal HSCs/MPPs did not exhibit increased AKT phosphorylation relative to adult HSCs/MPPs even though more fetal/neonatal HSCs/MPPs were in cycle ( Figures 1B-1E ). This suggests that while increased PI3-kinase pathway activation by Pten deletion can drive adult HSCs into cycle, sustained AKT phosphorylation is not observed in HSCs that divide frequently under physiological conditions. Consistent with this, Rictor deletion reduced AKT phosphorylation ( Figures 4M and  4N ) but had only modest effects on the maintenance and function of HSCs ( Figure 5 ). Nonetheless, Rictor was required for increased HSC proliferation ( Figure 6C ), HSC depletion ( Figures  6G-6K ), and leukemogenesis ( Figure 7) following Pten deletion. PTEN is therefore required in adult, but not neonatal, hematopoietic cells to maintain HSCs and to suppress leukemia by reducing mTORC2 activation. Rictor deletion also reduces the incidence of prostate cancer after Pten deletion, while having little effect on wild-type prostate epithelium (Guertin et al., 2009) . Our data indicate that mTORC1 and mTORC2 have distinct functions in dividing HSCs. While Rictor-deficient HSCs gave long-term multilineage reconstitution of irradiated mice (Figure 5) , Kalaitzidis et al. (2012) found that Raptor-deficient HSCs were unable to reconstitute irradiated mice. Fetal HSCs and cyclophosphamide/G-CSF mobilized HSCs exhibited increased mTORC1, but not mTORC2, activation relative to quiescent adult HSCs ( Figures 1D and 1G ). Rapamycin treatment, but not Rictor deletion, reduced HSC mobilization after cyclophosphamide/G-CSF treatment ( Figure 6F ). These results demonstrate that mTORC1 is more important than mTORC2 for the proliferation of HSCs under physiological conditions. In contrast, both mTORC1 and mTORC2 were activated by Pten deletion ( Figure 1D ). Rictor deletion, but not rapamycin treatment, reduced HSC mobilization after Pten deletion (Figure 6D) . Rapamycin treatment and Rictor deletion both reduced HSC proliferation after Pten deletion ( Figure 6C ) and additively reduced the severity of myeloproliferative disorder following Pten deletion ( Figure 7A ). These results demonstrate that mTORC2 is a major mediator of the effects of Pten deletion on hematopoietic cells, and that mTORC2 likely signals through mTORC1-dependent and mTORC1-independent pathways. Therefore both mTORC1 and mTORC2 contribute to the hematopoietic phenotypes observed after Pten deletion, consistent with our previously published results Lee et al., 2010) and the results in Kalaitzidis et al. (2012) .
Our data indicate that temporal changes in the regulation of the PI3-kinase pathway lead to temporal changes in the mechanisms that regulate HSC function and leukemogenesis. This likely explains why conditional deletion of Pten from fetal hematopoietic cells using VE-Cadherin-Cre does not lead to the development of leukemia until around 8 weeks after birth (Guo et al., 2008) . It is not yet clear why Pten deletion increases PI3-kinase pathway activation in adult, but not neonatal, HSCs. Neonatal HSCs were capable of activating the PI3-kinase pathway when cultured ( Figure 4D ), but exhibited a cell-autonomous difference relative to adult HSCs in their dependence upon PTEN in transplantation assays (Figures 2E-2H) . We have identified a number of gene products that are differentially expressed between neonatal and adult HSCs and that could potentially influence PI3-kinase pathway signaling ( Figure S2 ). However, much more work will be required to assess their functions in neonatal and adult HSCs.
Since neonatal HSCs and other hematopoietic cells can harbor mutations in Pten and p53 without transforming into leukemia until adulthood, our data suggest that mutated cells may persist for years in children before a change in developmental context renders these mutations competent to induce leukemia. Prolonged persistence of cells with leukemogenic mutations has been documented in human pediatric leukemia patients (Wiemels et al., 1999a (Wiemels et al., , 1999b . In the past, this latency has been attributed to the time necessary to accrue secondary mutations. However, our data suggest an additional explanation: that some of these mutations were not competent to cause leukemia until the blood cells matured into a susceptible developmental context. This could explain why T-ALL presents more commonly in older rather than younger children. Our findings raise the possibility of reprogramming therapies that are analogous to differentiation therapies. Reprogramming of adult hematopoietic cells to a fetal or neonatal identity (Kim et al., 2007; He et al., 2011) could blunt the effects of leukemogenic mutations that require an adult developmental context to induce neoplastic proliferation.
EXPERIMENTAL PROCEDURES Mouse Strains and pIpC Injections
Pten fl/fl mice, Mx1-Cre mice, and p53 À/À mice have been previously described (Jacks et al., 1994; Kü hn et al., 1995; Groszer et al., 2006) . These mice were all backcrossed for at least eight generations onto a C57BL/6Ka-Thy-1.1 (CD45.2) background. See the Supplemental Experimental Procedures for a description of the generation of Rictor fl allele. Expression of Mx1-Cre was induced by a single subcutaneous injection of pIpC (Amersham) in neonatal mice at P2 or by three intraperitoneal injections over 6 days in adult mice beginning 6 weeks after birth. pIpC dose was determined empirically for each lot so that >95% of HSC colonies exhibited complete recombination of the Pten fl/fl and Rictor fl/fl alleles ( Figures S1 and S4 ). Neonatal mice received 1-2 mg/dose, depending on pIpC lot. Adult mice received 10 mg/dose. All mice were housed in the Unit for Laboratory Animal Medicine at the University of Michigan (UM), where these studies were initiated, or at the Animal Resource Center at UT-Southwestern Medical Center, where the studies were completed. All animal procedures were approved by the UM and UT Southwestern Committees on the Use and Care of Animals.
Flow Cytometry and Isolation of HSCs
Bone marrow cells and splenocytes were obtained, stained, and analyzed by flow cytometry as previously described (Lee et al., 2010; Nakada et al., 2010) . Antibodies and detailed methods are in the Supplemental Experimental Procedures (Table S1 ).
BrdU Incorporation and Cell Cycle Analysis
BrdU (Sigma; diluted to 5-10 mg/ml in PBS) was administered by IP injections (100 mg/kg/dose) given every 8 hr beginning 24 hr prior to bone marrow harvest. HSCs were stained and enriched by c-kit selection as described in the Supplemental Experimental Procedures, and BrdU incorporation was measured by flow cytometry using the APC BrdU Flow Kit (BD Biosciences). For cell cycle analysis, HSCs were stained with antibodies against CD150, CD48, lineage markers, c-kit, and Sca-1. c-kit + cells were enriched by selection with paramagnetic beads (Miltenyi Biotec, Auburn, CA). The enriched cells were fixed and permeablized with cytofix/cytoperm buffer (BD Biosciences) then washed in staining medium, and stained with DAPI (20 mg/ml). HSCs were analyzed by flow cytometry. For analysis of AKT phosphorylation in HSCs/MPPs in different phases of the cell cycle ( Figure 1E ), Vybrant DyeCycle Violet Stain (Invitrogen) was used to analyze DNA content while preserving cell viability. A detailed protocol is provided in the Supplemental Experimental Procedures.
Western Blots
Twenty or thirty thousand CD48 À LSK cells were sorted and then resorted (to ensure purity) into Trichoracetic acid (TCA), and the volume was adjusted to a final concentration of 10% TCA. LSK cells were sometimes incubated at 37 C in Iscove's medium plus 2% fetal bovine serum for 30 min prior to protein extraction in 10% TCA. Extracts were incubated on ice for at least 15 min and centrifuged at 16,100 3 g at 4 C for 10 min. Precipitates were washed in acetone twice and dried. The pellets were solubilized in 9M urea, 2% Triton X-100, and 1% DTT. LDS loading buffer (Invitrogen) was added and the pellet was heated at 70 C for 10 min. Samples were separated on Bis-Tris polyacrylamide gels (Invitrogen) and transferred to PVDF membrane (Millipore). Antibodies are listed in the Supplemental Experimental Procedures (Table S1 ).
Western blotting was performed according to the protocol from Cell Signaling Technologies, and blots were developed with the SuperSignal West Femto chemiluminescence kit (Thermo Scientific). Blots were stripped (1% SDS, 25 mM glycine [pH 2]) prior to reprobing.
Long-Term Reconstitution Assays
Competitive reconstitution experiments were performed as previously described (Lee et al., 2010; Nakada et al., 2010) . A complete description of long-term reconstitution assays is provided in the Supplemental Experimental Procedures.
Survival and Leukemia Analysis
After administering pIpC to mice as described above, the mice were monitored daily and morbid mice were euthanized. Spleen and thymus tissues were fixed in buffered 10% formalin and embedded in paraffin for sectioning and hematoxylin and eosin (H&E) staining. Bone marrow cytospin specimens were Wright-Giemsa stained (Sigma). J.A.M., a pediatric hematologist, reviewed all slides and bone marrow specimens.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes five figures, three tables, and Supplemental Experimental Procedures and can be found with this article online at http://dx.doi.org/10.1016/j.stem.2012.05.026.
